

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Bionomics Limited
ABN 53 075 582 740

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Jonathan Lim
Date of last notice	12 December 2012

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	A) Indirect B) Indirect C) Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	A) Co-trustee of the Lim Family Trust B) Controlling of City Hill Venture Partners I, LLC
Date of change	6 January 2014
No. of securities held prior to change	A) 63,598 Listed Ordinary Shares B) 4,009,865 Listed Ordinary Shares C) 500,000 Unlisted ESOP Options
Class	A) Listed Ordinary Shares B) Listed Ordinary Shares C) Unlisted ESOP Options
Number acquired	A) 15,899 Listed Ordinary Shares B) 1,002,466 Listed Ordinary Shares
Number disposed	Nil
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Issued at a deemed price of \$0.4176
No. of securities held after change	A) 79,497 Listed Ordinary Shares B) 5,012,331 Listed Ordinary Shares C) 500,000 Unlisted ESOP Options

+ See chapter 19 for defined terms.

Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issued pursuant to an agreement completed on 14 September 2012 pursuant to which Bionomics Limited acquired Eclipse Therapeutics Inc (refer to announcement dated 17 September 2012). The initial tranche was issued in September 2012 and approved by shareholders at the 2012 AGM. This final balance is now being issued after the satisfaction of the relevant representations and warranties in line with the agreement.
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.